Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
EHMT2 (G9a) is a histone methyltransferase enzyme that primarily catalyzes the mono- and di-methylation of lysine 9 on histone H3 (H3K9me1 and H3K9me2), which are epigenetic marks associated with transcriptional repression. It is involved in gene silencing, DNA methylation, cell proliferation, and apoptosis. Dysregulation of EHMT2 is implicated in several cancers.
Inhibition of histone methyltransferase activity, preventing H3K9 methylation and subsequent gene silencing.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Euchromatic histone-lysine N-methyltransferase 2 (G9a).